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MORPHOLOGICAL DESCRIPTION 
 
Cannabis  is a genus of annual flowering plants that includes three putative 
species, Sativa, Indica and Ruderalis. These three taxa are indigenous to 
central Asia,  South Asia and North West of Himalayas1. (Fig.1) 
 
 
Figure 1 The three species of cannabis 
 
 
The leaves are palmately compound with serrate leaflets. The first pair of leaves 
usually has a single leaflet, the number gradually increasing up to a maximum 
of about thirteen leaflets per leaf (usually seven or nine), depending on variety 
and growing conditions. At the top of a flowering plant, this number again 
diminishes to a single leaflet per leaf. The lower leaf pairs usually occur in an 
opposite leaf arrangement and the upper leaf pairs in an alternate arrangement 
on the main stem of a mature plant. 
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Cannabis normally has imperfect flowers with pistillate "female" (Fig.2) and 
staminate "male" (Fig.3) flowers occurring on separate plants. It is  unusual, find 
true hermaphrodites plants in which there are bear staminate and pistillate 
structures on individual flowers. Male flowers are normally borne on loose 
panicles and female flowers are borne on racemes2.  
 
                
Figure 2 Cannabis female flowers             Figure 3  Cannabis male flowers                                                                         
 
The first publication about Cannabis was in 1785 when an evolutionary 
biologist, Jean-baptiste Lamarck,  published a description of a second species 
of Cannabis, which he named Cannabis indica L.. Lamarck based his 
description of the newly named species on plant specimens collected in India. 
He described C. indica as having poorer fiber quality than C. sativa, but greater 
utility as an inebriant3,4. In 1924, Russian botanist D.E. Janichevsky concluded 
that ruderal Cannabis in central Russia was either a variety of C. sativa or a 
separate species, and proposed C. sativa L. var. ruderalis Janisch. and 
Cannabis ruderalis Janisch. as alternative names. In 2002 Clarke and Watson 
proposed that the species Cannabis sativa would include all individuals, except 
perhaps the varieties used to produce hashish and marijuana in Afghanistan 
and Pakistan. 
Today, genetically the genus Cannabis was formerly placed in the Nettle 
(Urticaceae) or Mulberry (Moraceae) family, but is now considered along with 
hops (Humulus sp.) to belong to the Hemp family (Cannabaceae). 
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NATURAL CANNABINOIDS 
 
Cannabis plants produce a unique family of terpeno-phenolic compounds called 
cannabinoids, which are responsible of the so called "high feeling" that people 
experience from smoking marijuana. The cannabis usually produces 85 
different types of compounds  which belongs to the cannabinoid family5, but 
those that are  usually produced in greatest abundance are cannabidiol (CBD) 
and Δ9-tetrahydrocannabinol (THC), of these, only THC is psychoactive (Fig.4). 
These two cannabinoids have different concentrations in different organs of the 
plants but the highest concentration is found in the female flowers6. 
Since the early 1970s, Cannabis plants have been categorized by their 
chemical phenotype or "chemotype" based on the overall amount of THC 
produced, and on the ratio of THC to CBD. Although overall cannabinoid 
production is influenced by environmental factors, the THC/CBD ratio is 
genetically determined and remains fixed throughout the life of a plant. 
 
 
Figure 4 Molecular structures of CBD and THC 
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THE USE OF CANNABIS IN THE CENTURIES 
 
Cannabis Sativa is among the earliest plants cultivated by man. Infact the first 
evidence of the use of cannabis was found in China since 4.000 B.C. for the 
producting of Chinese manufactured strings, ropes, textiles, and even paper. 
Cannabis was also used as a medicine by ancient Chinese as was reported in 
the world's oldest pharmacopoeia, the Pen-ts'ao Ching which was compiled in 
2.700 B.C., in which  there was a lots of indications for the use of cannabis 
included: rheumatic pain, intestinal constipation, disorders of the female 
reproductive system, malaria, and between 110-207 A.D. was used to 
anesthetize patients during surgical operations in association with ethanol. 
The medical indications of cannabis, in the beginning of the 20th century, were 
summarized in Sajous's Analytic Cyclopedia of Practical Medicine (1924) in 
three areas: Sedative or Hypnotic (insomnia, melancholia,  and gonorrhea); 
analgesic (headaches, migraine, eye-strain, menopause, brain tumors, and for 
relief of dental pain), and other uses: for example to improve appetite and 
digestion, sexual atony in the female, and impotence in the male.  
Since the 1960's, the recreational use of cannabis rapidly spread among the 
younger ranges of the population throughout the Western world. In 1964, Gaoni 
and Mechoulam identified the chemical structure of Δ9-THC, which contributed 
to a proliferation of studies about the active constituents of cannabis7. 
The number of publications about cannabis reached their peak in the early 
1970's. In this period, a Brazilian research group, led by Carlini, gave a great 
contribution, especially about the interactions of Δ9-THC with other 
cannabinoids. Since then, Carlini has been developing efforts for the 
realignment of public policies concerning cannabis control8,9. After the middle of 
1970's, the number of publications started to slowly decline during the following 
two decades. The interest in studies about cannabis was renewed in the early 
1990's, with the description and cloning of specific receptors for the 
cannabinoids in the nervous system and the subsequent isolation of 
anandamide, an endogenous cannabinoid. Afterwards, the number of 
publications about cannabis has been continuously growing, attesting the great 
interest in research involving the herb. Figure 5 shows the evolution of the 
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number of publications about cannabis in the last 50 years.  
                                              
Figure 5 
“A. W. Zuardi History of cannabis as medicine, Review, 2006, Revista Brasileira de psiquiatria, vol 
28 n° 2.” 
With the growth of scientific interest for cannabis, its therapeutic effects are 
being once again studied, this time using more accurate scientific methods. 
There are studies, in different phases, about the therapeutic effects of Δ9-THC 
in conditions such as: epilepsy, insomnia, vomits, spasms, pain, laucoma, 
asthma, inappetence, Tourette syndrome, and others. Among the therapeutic 
indications of Δ9-THC the following are considered close to being proven: anti-
emetic, stimulant of appetite, analgesic, and in symptoms of Multiple Sclerosis. 
Other cannabinoids are also under investigation, such as Cannabidiol (CBD), 
which has evidence for therapeutic effects in epilepsy, insomnia, anxiety, 
inflammations, brain damage (as a neuroprotector), psychoses, and others like 
multiple sclerosis in which the benefic effects of cannabis has been scientifically 
proven. 
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ENDOCANNABINOID SYSTEM (ECS)  
Human body has an endogenous cannabinoid system that includes cannabinoid 
receptors (CB1 and CB2), their endogenous ligands, anandamide (AEA) and 2-
arachidonoyl glycerol (2-AG), the anandamide transporter protein, and two 
enzimes, fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL). 
(Fig.6) 
 
 
 
                                     
Figure 6  The  endocannabinoid system 
“Medical marjuana.com” 
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CANNABINOID RECEPTORS 
 
Untill now two cannabinoid receptors has been cloned, CB1 receptor was 
cloned in 1990 in rats by  Matsuda10, and next year in humans  by Gerard11. 
Instead CB2 receptor was cloned by Munro in 1993 from human myeloid cells12. 
CB1 receptor is mainly located in the terminals of nerve cells (central and 
peripheral neurons and glial cells), reproductive system (i.e. testis), some 
glandular systems, the microcirculation, muscle, gastrointestinal tract, pancreas, 
urinary bladder, lung, adrenal gland, testis, ovary, uterus and prostate. 
Instead CB2 receptor was located initially in the immune system, specifically in 
multiple lymphoid organs (spleen, tonsils and thymus) with the highest 
expression detected in B lymphocytes, moderate expression in monocytes and 
polymorphonuclear neutrophils and the lowest expression in T lymphocytes13. 
Finally CB2 receptor was found to be expressed also in brain microglial cells 
under inflammatory conditions, and recent studies using human neutrophils 
indicate that the CB2 receptor may suppress neutrophil migration during 
inflammation14.  
 
 
Figure 7 Different aminoacid compositions between the two cannabinoid receptors 
“Deficency of CB2 recetor in mice improves insulin sensitivity but increase food intake and 
obesity  with age”  
 
 
Cannabinoid receptors CB1 and CB2 exhibit 97 to 99 % amino acid sequence 
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identity across the species from which it was cloned: rat, mouse and humans. 
The preservation of this ancient signaling system in vertebrates and several 
invertebrate phyla reflects the important functions played by endocannabinoids 
in cells and system physiology15. CB2 receptor exhibit 44% homology with the 
CB116 increasing to 68% identical amino acid identity when only the seven 
transmembran domains are considered. Furthermore, the amino terminal 
domain of the  human CB2 receptor is much shorter than, and has no 
significant conservation with, the human CB1 receptor.  
Both CB1 and CB2 receptors are G protein-coupled receptors that traverse the 
plasma membrane seven times and regulate the activity of intracellular effectors 
through activation of intracellular G proteins16.  
Heterotrimeric G proteins are composed of three distinct subunits, α (39–50 
kDa), β (35–36 kDa), and γ (6–10 kDa) and their activation by G protein-
coupled receptors produces an exchange of GTP for GDP on the subunits. This 
results in the dissociation of the G protein from the receptor and the separation 
of the α-GTP from the βγ subunits. Both the free α-GTP and βγ subunits 
proceed to regulate various downstream effectors17. Pertussis toxin (PTX)-
sensitive G proteins (i.e., Giα and Goα-subtypes) appear to mediate the 
physiological effects of cannabinoids acting on CB1 and CB2 receptors18. 
However, other studies also suggest that CB1 receptors may regulate 
intracellular signaling via PTX-insensitive Gsα as well19,20. 
Transduction mechanisms of CB1 receptor involve inhibition of cAMP 
production through inhibition of adenylate cyclase, inhibition of calcium influx, 
activation of potassium channels, and activation of the mitogen- activated 
protein kinase (MAPK) that induce cellular proliferation. The mammalian MAPK 
family consists of three subfamilies with multiple members: the extracellular 
signal-regulated kinases (ERK), the Jun amino-terminal kinases/stress- 
activated kinases (JNK/SAPK), and the p38 MAPKs. While ERK is involved in 
regulation of cell division and growth, the other two subfamilies are activated by 
stress signals and inflammatory cytokines and have been related with cellular 
death and immune disorders.  
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Figure 8 Intracellular pathway after CB1 stimulation. 
“A.A. Groul, L.A. Serbero, J.Bozzo,The year’s Newdrug and Biologies, Drug News and perspective, 
2007, vol 20, pag 17” 
   
 
Two main mechanisms have been identified for the transduction machanisms of  
CB2 receptor: inhibition of adenylate cyclase and stimulation of MAPK. 
Furthermore unlike CB1 receptor, the CB2 receptor does not have effect on ion 
channels. In addition, the activation of CB2 receptors has been also linked to 
the stimulation of additional intracellular pathways including the 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which has been associated 
with pro-survival effects, and the de novo synthesis of the sphingolipid 
messenger ceramide, which is involved in the pro-apoptotic effects of 
cannabinoids16. 
 
 
 
 
 
 14 
 
Figure 9 Intracellular pathway after CB2 stimulation 
 
Pharmacological studies revealed the existence of other endocannabinoid 
targets including the vanilloid receptor16 and at least two non-CB1 non-CB2 
‘CB-like’ receptors, one in the vascular bed and the other in glutamatergic 
axon terminals21. The existence of these and other putative cannabinoid 
receptors, and their role in endocannabinoid physiology can be clarified only 
after their molecular characterization. 
Recent molecular biology research carried out in 2007 by E.Ryberg suggested 
that the orphan receptor GPR55 should be characterized as a cannabinoid 
receptor, on the basis of sequence homology at the binding site. Subsequent 
studies by E. Lauckner in 2008, showed that  GPR55 is highly expressed in 
large dorsal root ganglion neurons and, upon activation by various 
cannabinoids (Δ9-THC, the anandamide, analog methanandamide, and 
JWH015) increases intracellular calcium in these neurons. Except for the 
jejunum and ileum this receptor is not expressed in the periphery22,23. Finally, 
GPR119 has been suggested as a fourth possible cannabinoid receptor. 
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ENDOCANNABINOIDS 
The discovery of natural cannabinoids molecule, Δ-9 THC and CBD, and the 
CB1 receptors leads to research of endocannabinoids. In 1992 Mechoulam and 
his research laboratory isolated, from porcine brain, a lipid molecule, the 
arachidonyl-ethanolamide, and this compound was called Anandamide (AEA)24. 
In 1995 Mechoulam discover another endocannabinoid called 2-
arachidonoylglycerol (2-AG), isolated from canine gut25 and later observed in 
mouse neuroblastoma cells from Di Marzo et al.in 199726. Recent studies 
suggest that 2-AG is a full agonist of CB2 receptor, while anandamide is just a 
partial agonist of this receptor, highlighting the different phisyological role of 
these endocannabinoids 27. 
 
 
Figure 10 The endocannabinoids 
 
Human body produces the endocannabinoids from arachidonic acid which 
resembles other lipid transmitters without the need of storing in synaptic 
vesicles. The synthesis of anandamide is Ca2+-dependent and is locally 
produced by the phospholipase D-mediated cleavage of the membrane 
precursor called N-arachidonoyl-phosphatidylethanolamine (NArPE)28. Whereas 
the synthesis and release of 2-AG is different from that of anandamide. 
Because 2-AG is a monoglyceride, its formation is closely associated with the 
metabolism of triacylglycerol, mainly by the receptor-dependent activation of 
phosphatidylinositol-specific phospholipase C (PLC). 
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Figure 11 Biosynthesis of the 2-AG and AEA. 
“V.Di Marzo, M.Bifulco. The endocannabinoid system and its therapeutic Exploitation, Nature 
Review 3, 2004, Vol 3, pag 771-784” 
 
The 2-AG regulation is independent of anandamide synthesis and its release. 
Once anandamide and 2-AG are formed, they target the CB receptors in the 
same cell where they were formed, via diffusion within the plasmalemma, or 
they can be released to the extracellular fluid where they reach distant targets 
(i.e. presynaptic terminals) with the apparent help of protein carriers such as 
lipocalins or albumin30. These endocannabinoids have been found in the brain, 
plasma and peripheral tissues. In the brain, the concentration of anandamide is 
200-fold lower than that of 2-AG27. In brain, they are produced by neurons at 
their sites of action and act on demand, generating a transient, rapid effect 
before being hydrolyzed and inactivated by fatty acid amide hydrolase (FAAH), 
which breaks the amide bond and releases arachidonic acid and ethanolamine 
28,29. 
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PHYSIOLOGICAL FUNCTIONS OF 
ENDOCANNABINOID SYSTEM 
The endocannabinoid system has been implicated in a growing number of 
physiological functions, both in the central and peripheral nervous system and 
in peripheral organs. More importantly, modulating the activity of 
endocannabinoid system turned out to hold therapeutic promise in a wide range 
of disparate diseases and pathological condition.   
Cannabinoids are best known for their effects on CNS functions. They produce 
euphoria, alterations in cognition and analgesia, have anticonvulsivant 
properties and affect on temperature regulation, sleep and appetite. However, 
cannabinoids also possess immunomodulatory activity and anti-inflammatory 
properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 12 Therapeutic effects of cannabis 
“www.cnsforum.com” 
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PHARMACOLOGICAL ROLE OF CB2 RECEPTOR 
 
The physiological and putative therapeutic potential of the CB2 receptor largely 
remains unexplored; however, recent data indicate that CB2 cannabinoid 
receptors participate in the control of peripheral pain, inflammation, 
osteoporosis, growth of malignant gliomas, tumors of immune origin, and 
immunogical disordes such as multiple sclerosis. Recent studies have now 
implicated CB2 receptor in neuroprotective activity of cannabinoids, mainly 
through a series of glia- dependent anti-inflammatory actions31.  
 
 
 
 
 
Figure 13 A review of pharmacological role of CB2 receptor in human body 
“ Emerging Clinical application for cannabis and cannbinoid, Review of the recent Sientific 
Literature 4th edition” 
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NEUROPROTECTION 
 
Most neurodegenerative diseases are associated with chronic and acute 
inflammation resulting from the activation of brain mononuclear phagocyte cells, 
called microglial cells. In fact has been shown by the increased proliferation of 
microglial cells in brains of patients with multiple sclerosis (MS), Alzheimer's 
disease (AD), and amyotrophic lateral sclerosis (ALS). 
Microglial cells are the resident macrophage of the CNS. In healthy brain, they 
are in a resting state, but pathological conditions induce their activation during 
which they change to on amoeboid shape, up-regulate the cell-surface 
expression of a variety of surface antigens and secrete several pro-
inflammatory molecules including interleukin-1β, tumor necrosis factor-α, nitric 
oxide, oxygen radical, glutamate, proteases. So microglia cells contribute32 to 
apoptotic cells or neuron debris during neurodegenerative disorders, can be 
detrimental to the survival of neighboring cells. 
Constitutive CB2 receptor expression is quite restricted in the CNS, being 
localized to specific nuclei of the brain stem33. Nevertheless, while resting 
microglia express little if any CB2, as proven by reverse transcription-PCR of 
healthy brain parenchyma, the expression of this receptor is induced under 
specific pathological conditions, including multiple sclerosis and amyotrophic 
lateral sclerosis34. Several reports have shown the role of CB2 receptors in 
activated microglia, which includes regulation of cytokine release and cell 
proliferation; all these effects lead to neuroprotection. This neuroprotection 
might be relevant for the treatment of both acute brain injuries (e.g. cerebral 
ischemia and trauma) and chronic neurodegenerative disorders35. 
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ALZHEIMER’S DISEASE 
 
Alzheimer’s disease (AD) is a chronic degenerative disorder of the brain and 
accounts for the most common form of dementia in the elderly. The 
histopathology of AD is currently well known thanks to the studies of Giulian et 
al. in 199936. AD is characterized by β-amyloid (A-β) deposition in senile 
plaques, neurofibrillary tangles, selective neuronal loss, progressive cognitive 
deficits, and reactive gliosis. The last mentioned involves both microglia, which 
attack the senile plaque, and astroglia, which surround the plaque complex and 
play a critical role in AD inflammation37, inducing a chronic inflammatory 
response that leads, among other events, to the activation of both microglia and 
astroglia. These are known to play a relevant pathophysiological role, because 
they produce abundant proinflammatory substances that initiate a secondary 
damaging process. FAAH protein and CB2 receptor protein are overexpressed 
in glial cells that are linked to the inflammatory process that accompanies 
Alzheimer’s disease, instead CB1 receptor density is not modified in the vicinity 
of these pathological structures. Moreover, FAAH expression appears to be 
restricted to reactive astrocytes, and CB2 receptors are expressed only in 
activated microglial cells38.The activation of CB2 recptor have shown that 
cannabinoids prevent A-β induced neurodegeneration by reducing microglial 
activation.  
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AMYOTROPHIC LATERAL SCLEROSIS (ALS) 
 
Amyotrophic lateral sclerosis (ALS), is a neurodegenerative disease 
characterized by rapid progressive degeneration of motor neurons in brain and 
spinal cord, paralysis and death within 2-5 years from the diagnosis. It is the 
third most common neurodegenerative cause of adult death, after Alzheimer’s 
disease and Parkinson’s disease. Most cases of ALS are sporadic and are 
probably acquired, while approximately 10% are familial. Despite a variety of 
putative underlying oxidative stress, neuroinflammation, autoimmunity, a defect 
in neuronal glutamate transport, glutamate toxicity and mutations of superoxide 
dismutase gene seem to be responsible. In 2002 Mc Geer and Mc Geer  
discover the inflammatory process of ALS 39; in 2005 Weidt and Moller discover 
the chronic inflammation in the same disease 40. 
In 2002 Shoemaker found elevated levels of CB2 receptors in microglia isolated 
from post-mortem human spinal cord of ASL patients, his studies continued until 
the discovery that, mRNA  receptor binding and function of CB2, but not CB1, 
receptors are dramatically and selectively up-regulated in spinal cords of  
transgenic mice in a temporal pattern paralleling disease progression. More 
importantly, daily injections of the selective CB2 agonist AM-1241, initiated at 
symptom onset, increase the survival interval after disease onset by 56%.   
These results suggest that CB2 agonists may be effective as pharmacological 
agents with several distinct advantages for the management of this disease. So 
CB2 agonist may ultimately be developed as novel therapeutic drugs that can 
be administrated alone or in combination with other agents at symptom 
oneset41. 
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MULTIPLE SCLEROSIS 
 
Multiple sclerosis (MS) is an autoimmune desease in which our ’own body’ 
immune system attaks and damages the myelin, a fatty sheath that sorrounds 
the axon, and with this damage the axon can no longer correctly conduct the 
signal as shown in  Figure 14  .                  
 
 
                                   
 
Figure 14  An  example of myelin damage caused by multiple sclerosis disease 
 
                       
In neurons the activation of CB1 receptor reduces the glutamate  release having 
a neuroprotection action in MS. The stimulation of CB2 receptor of the microglia 
and macrophage reduces the inflammatory citokines, the cell proliferation, 
chemiotaxis and the release of NO which have a anti-inflammatory action in 
MS42.  
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A report also allowed to extend to non-CB1 and non-CB2 receptors the 
inhibitory action of cannabinoids on astrocyte activation, suggesting a role for 
these receptors in the anti-inflammatory effects of exogenous and endogenous 
cannabinoids in MS, as shown in figure 15 42. 
 
 
   
 
 
 
Figure 15 
“www.healthandphysicaleducationteacher.com” 
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GLAUCOMA 
 
According to Merck home edition dictionary Glaucoma is an eye disorder in 
which the optic nerve suffers damage which this causes a permanent damage 
in the vision of the affected eye(s) progressing to complete blindness if left 
untreated.  
It is often, but not always, associated with increased pressure of the fluid in the 
eye (aqueous humour). The term ”ocular hypertension” is used for cases having 
a constantly raised intraocular pressure (IOP) without any associated optic 
nerve damage. Conversely, the term “normal” or “low tension glaucoma” is 
suggested for the typical visual field defects when associated with a normal or 
low IOP. 
The nerve damage involves loss of retinal ganglion cells in a characteristic 
pattern. There are many different subtypes of glaucoma, but they can all be 
considered a type of optic neuropathy. Raised intraocular pressure is a 
significant risk factor for developing glaucoma (above 21 mmHg or 2.8 kPa). 
One person may develop nerve damage at a relatively low pressure, while 
another person may have high eye pressure for years and yet never develop 
damage. Untreated glaucoma leads to permanent damage of the optic nerve 
and resultant visual field loss, which can progress to blindness. (Fig. 16) 
 
 
Figure 16 The consequences of glaucoma disease on optic nerve 
“www.webmd.com/eye-health/glaucoma-eyes” 
 
After the discovery made  by Straiker of CB receptors at the ocular level, 
studies have begun to determine whether and  how this system might be 
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involved in physiologic and/or pathologic process of the eye;  endocannabinoids 
such as 2-AG and anandamide, have been found  able to produce neuro-
protection at level of the retina. 
Recent studies demonstrate that CB1 receptors are expressed in eye and CB2 
are also expressed in the retina and trabecular meshwork. 
The presence of CB receptors in the eyes means that  endocannabinoids in the 
eye heave a role in ocular physiology; in fact several studies by Devane43, and 
then Laine and Andh Chien respectively in 2002 and in 2003 show that topical 
administration of CB1 agonists WIN-55212-2, lowers IOP in rabbits, in  non 
human primates and glaucomatous humans possibly due to an increase in 
humor aqueous outflow and are also involved in a neuroprotective actions in the 
eye44-45. 
The first studies on the IOP-reducing effects of CBs date back to the 1970s. 
Hepler and Frank in 1971 found that eating or smoking marijuana reduced IOP 
by 5–45% (mean, approximately 25%). However, since the effect lasted for only 
3–4 h, patients would have to use cannabis 8–9 times a day to keep their IOP 
under control. The beneficial effects of marijuana on ocular hypertension were 
also accompanied by several toxic effects, including orthostatic hypotension, 
increased heart rate, emphysema-like lung changes, diverse alterations of the 
mental state (euphoria, reduced attention, short-term memory deficits, and 
altered motor coordination), and, at the ocular level, they included conjunctival 
hyperemia associated with a 50% reduction in tear secretion34. To avoid these 
problems many different new  compounds, called soft-drugs have been 
synthesized46. 
Soft drugs are bioactive molecules deliberately designed to go through a rapid, 
efficient, and predictable metabolic inactivation after having exerted their effects 
at the site of action. In many cases the use of soft drugs has led to the 
development of safer marketed drugs since they are endowed with the 
appropriate local activity, whereas they are devoid of systemic side effects. The 
soft drug approach would, therefore, be particularly suitable for the development 
of cannabinoids to be used as locally active analgesic or anti-glaucoma agents, 
without causing the unwanted central effects.  
These considerations have already inspired some excellent examples of ‘soft-
cannabinoids’ possessing CB1-mediated IOP lowering properties, to be 
developed as safe anti-glaucoma agents46 
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ANTICANCER ACTION OF CANNABINOID RECEPTORS 
 
 
Cancer is a term used for a lot of different diseases each of them characterized 
by uncontrolled division of cells and  their ability to spread. This unregulated 
growth has many causes like mutations, defect in cell cycle and in apoptotic 
mechanism, but after all the common cause is represented by a damage in the 
DNA chain.  
Evidence accumulated within the last decade suggests that CB receptor 
agonists may have antitumour properties in a variety of cancer types; this topic 
has been reviewed in several cancer-related journals. Recent developments 
and insights are discussed with respect to CB receptor signalling, ligand 
selectivity, specificity of effect in different tissues and potential therapeutic 
relevance. 
In 1975, Munson reported for the first time that cannabinoids can reduce tumour 
growth and viability of lung cancer cells in vitro as well as in vivo. After this initial 
observation another 20 years passed until more detailed investigations yielded 
further insights into the anticancer mechanisms of cannabinoids. However, the 
mechanism of action of CB receptor ligands has started to become uncovered 
only recently. While some signalling events involved in the cytotoxic effects 
exerted by cannabinoids apply for all cellular models, other cellular mechanisms 
are restricted to only a few cell types. Thus, an important question is how CB 
receptor activation ultimately leads to inhibition of tumour growth and apoptosis 
of cancer cells47. 
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Figure 17 
“S.Sarfare, W.Adhani, H.Mukhart, Cannabis for cancer treatment, Progress and promises, Cancer 
Research, 2008, vol 8, pag 339” 
 
The figure above represents the signaling pathways associated by the 
activation of cannabinoid receptor mediated by its agonist. 
The inhibition after the binding is caused by the inhibition of cAMP-dependent 
PKA which activates a mitogen-activated protein kinases (MAPK). The 
stimulation of ceramide synthesis, due to the up-regulation of serine 
palmitoyltransferase (STP) leading to the subsequent induction of apoptosis. 
Cannabionoids receptor agonist also activates MAPKs and PI3K/Akt pathways 
which, by the activation of ERK1/2, leads to a modulation of cell cycle and 
arrest it in G1. 
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INHIBITION OF TUMOR ANGIOGENESIS 
 
 
Angiogenesis is the process of blood vessel formation, it is regulated by 
differents factors, the most important being vascular endothelial growth factor 
(VEGF). Angiogenesis is a phisiological mechanism involved, for example, in 
the ovarian cycle and in many ophthalmic and rheumatic diseases, but it is also 
essential for supplying nutrients to the tumor development48. Much effort has 
been directed towards the development of antiangiogenic agents that disrupt 
this process. In fact in 2000 Liu  discovered that vascular endothelial cells 
express functional CB1; in 2003 Blazquez complete the discovering noting that 
also CB2 receptors are expressed in endotelial cells49. 
The anticancer effect by cannabinoids has been associated with cannabinoid 
receptor-mediated deregulation of tumor angiogenesis in a variety of cancer 
models, in vitro and in vivo50. 
 
 
 
Figure 18 A review of physiological mechanism of neoangiogenesis. 
“S.Fogli, M.C Breschi, The molecular bases of cannabinoid action in cancer, 2007, Cancer therapy, 
vol 6, pag 103-116”  
 
Tumors promote angiogenesis by secreting proangiogenic cytokines, which 
induce the formation of blood vessels. In 2003 Blazquez tested a CB1-CB2 non 
selective agonist , JWH-133, and noticed an inhibition of angiogenesis not only 
by targeting vascular endothelial cells directly but also by interfering with 
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proangiogenic factor expression. Cannabinoid reduce  the VEGF, and 
angiopoietin-2(Ang2) which also contributes to the angiogenic process by 
preventing vessel maturation. 
At last treatment with cannabinoids also decreases the activity and expresssion 
on matrix metalloproteinase-2(MMP-2), a proteolitic enzyme that allows tissue 
breakdown and remodelling during invasive angiogenesis, whereas tissue 
inhibitor of metalloproteinase-2(TIMP-2)expression remains unaffected51. 
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INTRODUCTION TO EXPERIMENTAL PART 
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Cannabinoids are present in Indian hemp, Cannabis sativa L., and has been 
used since antiquity as medicinal agents. Interest in cannabinoid pharmacology 
has rapidly increased since the discovery of the endocannabinoid system (ECS) 
and over the past 15 years a considerable number of studies have been 
conducted in order to understand the biological role of the ECS and its 
regulatory functions in health and disease.  
 
  
 
Figure 19 The functions of ECS 
“www.gwpharm.com/metabolic-syndrome.aspx” 
 
The ECS consists of the G-protein coupled cannabinoid receptors, the 
endogenous ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), 
metabolizing enzymes (fatty acid amide hydrolase and monoglyceride lipase), 
and a specific cellular uptake system (the anandamide transporter protein). To 
date, two distinct cannabinoid receptors, CB1 and CB2, have been identified in 
mammalian tissues and cloned.  
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Figure 20 A 3D recostruction of seven transmembrane domains of CB receptors 
 
These receptors belong to the superfamily of G-protein-coupled (GPCR) seven-
transmembrane receptors, which negatively regulate adenylate cyclase. The 
CB1 receptor appears to be responsible for most of the centrally mediated 
effects of cannabinoids. In fact it is mainly located in the central nervous 
system, with the highest density in the cerebellum, the basal ganglia, and some 
regions of the globus pallidus. It is also present in peripheral organs such as the 
adrenal glands, bone marrow, lung, testis, and uterus.  
 
 
 
Figure 21 Localization of CB receptors  
 
The human CB2 receptor shares 44% homology with the CB1 receptor. 
Intracellular CB2-dependent signaling pathways include Gi/o-dependent 
inhibition of adenylyl cyclase, stimulation of mitogen-activated protein kinase 
and phosphoinositide 3-kinase pathways, and activation of de novo ceramide 
production or cyclooxygenase-2 induction. Initial studies revealed that this 
receptor was expressed exclusively in peripheral tissues, particularly under 
pathological conditions. In addition, it has been recently recognized that CB2 
receptor may play a functionally relevant role in the central nervous system. In 
fact CB2 receptor immunoreactivity has been shown in activated microglia in 
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affected regions of multiple sclerosis and amyotrophic lateral sclerosis. 
Furthermore, various studies have shown that the activation of CB2 receptor 
could block activation of microglia cells, but has little effect on the normal 
functioning of neurons within the CNS. The potential therapeutic targets for CB2 
receptor ligands include neuropathic and inflammatory pain, multiple sclerosis, 
amyotrophic lateral sclerosis, Huntington’s disease, stroke, atherosclerosis, 
gastrointestinal inflammatory states, chronic liver diseases  and cancer. 
Furthermore numerous pharmacological studies have shown that CB2 receptor 
ligands might directly inhibit tumor growth in vitro and in animal models The 
responsible mechanisms may involve cytotoxic or cytostatic effects, apoptosis 
induction, anti-metastatic effect accompanied by inhibition of neo-angiogenesis 
and tumor cell migration.  
 
 
 
Figure 22 Physiological role of CB2 receptor 
 
For all these reasons, the development of potent, selective CB2 molecules that 
are devoid of CB1 receptor mediated psychotropic side effects has gained 
interest as a new target in drug discovery. 
Recently models of the CB1 and CB2 receptors were generated using the 
bovine rhodopsin structure determined at 2,8 Å as a template and using an 
automated docking approach (AUTODOCK 3.0). The optimization of the model 
had been obtained through docking of WIN55212-2, agonist CB1 and CB2, 
Anandamide which has a completely different structure with respect to 
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WIN55212-2 and of relevant literature indole ligands that probably interact in the 
same WIN 55212-2 binding site52. 
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Figure 23 WIN55212-2                                    Figure 24 Anandamide 
 
An analysis of some agonists interaction with both receptors showed that 
CB2/CB1 selectivity is mainly determined by the interaction of ligands with the 
non-conserved residues S3.31(112) and F5.46(197). These residues are 
localized in the binding pocket that is delimited by TM3, TM4, TM5 and TM6 of 
CB2 receptor. 
                 
A                                                                B 
Figure 24 Binding pocket of CB1 receptor (A) and CB2 receptor (B) 
 
From this knowledge in our research laboratory it had been developed a study 
that achieved to the synthesis of 1,8-naphthyridin-4-one derivatives with general 
structure A. Binding results showed that these compounds generally exhibit a 
higher affinity for CB2 than for CB1 receptor with Ki value <20nM for CB2 
receptor. Moreover, the [35S]GTPγ binding assay and functionally studies on 
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human basophils indicated that these derivatives behaved as CB1 and CB2 
receptor agonists53. 
 
N N
O
N
H
O
R2
R1
A
 
 
Docking studies of derivative A into the CB1 and CB2 receptor models showed 
that these ligands present similar orientation in both receptors and were 
inserted in the extracellular side of the TM3-TM6. In particular, in the CB2 
receptor binding site the naphthyridine ring interacted with W5.43(194), 
M6.55(265) and L6.59(269). The substituent R1 (i.e. morpholine ring) was  
inserted between TM3 and TM4, and interacted with L3.27(108), P4.60(168), 
and L4.61(169), forming an H-bond with non-conserved S3.31(112) 
(corresponding to glycine in the CB1 receptor . Finally, R2 substituent (i.e. 
cyclohexyl) interacted with W6.48 (258) and, in particular, with the non-
conserved F5.46 (197) (corresponding to valine in the CB1 receptor). 
 
 
Figure 25 Docking of the N-cyclohexyl-1-(2-morpholin-4-ylethyl)-1,8-naphthyridin-
4(1H)-on-3-carboxamide into CB2 receptor models 
 
 
The analysis of this class of cannabinoid ligands suggests that the three most 
important pharmacophoric features for CB2 receptor affinity and CB2/CB1 
selectivity are a lipophilic central core connected with a non-aromatic 
carboxamide group in position 3 able to interact with the non conserved 
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F5.46(197) and a lipophilic substituent in position 1 with the nonconserved 
residue S3.31 (112). The important role of S3.31(112) and F5.46(197) has also 
been confermed by sitedirected mutagenesis data.  Following this binding 
hypothesis, we investigated possible modifications of the 1,8-naphthyridin-
4(1H)-one central scaffold in order to evaluate the chance of adding new 
interactions in the CB2 receptor model while maintaining those with S3.31(112) 
and F5.46(197). For these reasons 1,8-naphthyridin-2-(1H)-on-3-carboxamide 
of general structure B were synthesized. 
N N
N
H
O
O
R2
R1
B  
 
Docking studies of these derivative into CB2 receptor model showed that R1 
(i.e. morpholine ring) and R2 (i.e. cyclohexyl) substituents maintained the same 
interactions as compounds A. In addition, unlike compounds A, the 3-carbonyl 
group formed a H-bond with T3.33(114). 
 
 
Figure 26 Docking of the N-cyclohexyl-1-(2-morpholin-4-ylethyl)-1,8-naphthyridin-
2(1H)-on-3-carboxamide into CB2 receptor model. 
 
The new compounds were tested in competitive binding assays toward both 
human recombinant CB1 (hCB1) and CB2 (hCB2) cannabinoid receptors 
expressed in CHO cells and were found to be selective for CB2 receptor (Table 
1). Some of the new tested compounds exhibited a subnanomolar CB2 receptor 
affinity and a high selectivity over CB1 receptor. Furthermore, the 
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concentration–dependent inhibitory action on human basophils activation and 
the concentration-dependent decrease of cell viability in Jurkat cells shown that 
these derivatives possess agonist properties at CB2 receptor54.   
 
Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 In order to obtain a more pronounced effect in terms of CB2 affinity and 
selectivity, the goals of my thesis were: 
- introduce new substituents in position 1 of the 1,8-naphthyridin-2-(1H)-on-    3-
carboxamides of general structure B;  
- introduce various substituents in position 6 of the 1,8-naphthyridine nucleus. 
Comp. R1 R2 Ki CB1 (nM) 
KiCB2(n
M) 
KiCB1/ 
KiCB2 
B1 ethylmorph. cyclohexyl 560 7.9 71 
B2 benzyl cyclohexyl 560 31 18 
B3 p–fluorbenzyl cyclohexyl 56 2.2 25 
B4 n–butyl cyclohexyl 5600 70 80 
B5 ethylmorph. 4–methylcyclohexyl 1000 1.9 526 
B6 benzyl phenethyl NT NT NT 
B7 benzyl 4–fluorophenethyl 6947 69.8 100 
B8 benzyl cycloheptyl 960 22 44 
B9 p–fluorbenzyl cycloheptyl 9.6 0.7 14 
B10 ethylmorph. cycloheptyl 18 3 6 
B11 benzyl 4-methylcyclohexyl 1600 7.8 205 
B11trans benzyl 4–methylcyclohexyl 5255 39.8 132 
B11cis benzyl 4–methylcyclohexy 1519 5.8 262 
B12 p–fluorbenzyl 4-methylcyclohexyl 200 0.9 222 
B12trans p–fluorbenzyl 4–methylcyclohexyl 300 9.0 33 
B12cis p–fluorbenzyl 4–methylcyclohexyl 200 0.7 286 
SR144528   437 0.6 728 
JWH-133   677 3 226 
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The results of CB1 and CB2 receptors binding assays of the newly synthesized 
CB receptors ligands may be useful to increase our  knowledges about the 
structure-activity relationships for this class of compounds. 
For these reasons in the first part of my thesis, I synthesized compounds C1-
C8.  
 
N N
N
H
O
O
R
C1-C8
 
 
 
 
 
C1: R=    ;                   C2: R= ;  
C3: R=; O
O
 ;      C4: R= O
O
;  
C5: R= O
O
;       C6: R= OH
O
 ;   
C7: R= OH
O
;             C8: R= OH
O
  
 
 
The compounds C1 and C2 are characterized in position 1 of the 1,8-
naphthyridine nucleus by n-butyl or n-pentyl group which recently were found to 
be suitable substituents in CB2 ligands structurally similar to our compounds.  
The choice of introducing ester groups in position 1 of the 1,8-naphthyridine 
nucleus as in compounds C3-C5 was motivated by the possibility of finding 
further confirms the use of ester derivatives as soft-drugs. Soft drug are 
bioactive molecules which will go through a rapid metabolic inactivation after 
having exerted their effects at the site of action. I have also synthesized the 
corresponding carboxylic acid C6-C8 which were hypothesized as major 
metabolite of C3-C5, in order to test their  affinity towards the CB2 and CB1 
receptors. Finally the N-4-methylcyclohexyl carboxamide in position 3 of the 
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1,8-naphthyridine nucleus has been selected on the basis of the binding results 
obtained for the derivatives B on CB2 receptor.  
The synthesis of compounds C1-C8 is outlined in Scheme 1. The heating of 2-
aminopyridin-3-carboxaldheyde with diethyl malonate and in presence of 
piperidine in EtOH at reflux for 24 h afforded the 1,8-naphthyridin-2(1H)-on-3-
carboxylic acid ethyl ester 1. The treatment of ethyl ester 1 with the 4-
methylcyclohexylamine in sealed tube for 24 h at 120°C provided the desired 
carboxamide 2. The N1-alkylation of carboxamide 2 in anhydrous DMF with the 
suitable alkyl halide or alkyl ester halide in the presence of NaH for C1 and C2 
or cesium carbonate for C3-C5 at 25-70°C for 12 h afforded the desired 
compounds C1-C5. The ester derivatives C3-C5 were then treated with NaOH 
10% at 110°C for 2-6 h to obtain the corresponding carboxylic acid C6-C8. 
 
In the second part of my thesis, in order to obtain compounds that could provide 
additional interactions with the CB2 receptor binding site compared to 
compounds of type B, I synthesized D1-D5 and E1-E5 which are characterized 
by various lipophilic groups in position 6 of the 1,8-naphthyridine core. 
The aliphatic carboxamide group in position 3 of the 1,8-naphthyridine nucleus 
is the same as that  of compounds C, and the p-fluorobenzyl and 
ethylmorpholino substituents in position 1 have been selected on the basis of 
the binding results obtained for the derivatives B on CB2 receptor.  
 
N N
R
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O
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D1-D5
N N
R
N
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O
N
O
E1-E5
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                 D2, E1: R= Br; 
                  D1, E2: R= O ;            D3, E3: R=
O
 
 
                   D4, E4: R=
S
   ;                              D5, E5: R= F  
 
The synthetic routes to obtain compounds D1-D5 are depicted in Scheme 2 and 
3.  
The Scheme 2 describe the synthesis  of  derivative D1. The 2-aminopyridin-3-
carboxaldheyde was treated with Br2 in glacial acetic acid at room temperature 
for 24 h to obtain the corresponding 6-bromo derivative 3 which was refluxed 
with diethyl malonate and in presence of piperidine in EtOH for 24 h to afford 
the 6-bromo-1,8-naphthyridin-2(1H)-on-3-carboxylic acid ethyl ester 4. 
Initially to obtain the derivative 4 the 1,8-naphthyridin-2(1H)-on-3-carboxylic acid 
ethyl ester 1 was treated with Br2 in the same conditions above reported, but the 
yield was very low. 
 
N N
H
O
O
O
Br2 ;AcOH
N N
H
O
O
O
Br
 
 
The compound 4 was then treated with the 4-methylcyclohexylamine in sealed 
tube for 24 h at 120°C to obtain the carboxamide 5 (Scheme 2).  
To obtain the compound D1, the 6-bromoderivative 5 was subjected to a Cross 
Coupling reaction with 4-methoxyphenyl boronic acid in dioxane under the 
Suzuki condition using Pd(Ph3)4 as catalyst and Na2CO3 2 M as base (Scheme 
2). The palladium(0) compound required in this cycle, 
di(triphenylphosphine)palladium(0), is prepared in situ from a palladium(II) 
precursor using PPh3 and Pd (OAC)2  (Fig.27). 
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Figure 27 The catalitic cycle of Suzuki reaction 
 
This reaction, carried out in microwave (CEM) at 150°C for 15 min (power 
200W, pressure 100 psi, stirring on), lead to a crude mixture that was purified 
by flash-chromatography (hexane: ethyl acetate 1:1) to obtain the compound 5-
methoxyphenyl substituted 6 in 50% yield. The treatment of derivative 6 in 
anhydrous DMF with cesium carbonate for 1 h under stirring at room 
temperature and then with p-fluorobenzyl chloride at 50°C for 24 h gave the 
desired compound D1 purified by flash-chromatography using hexane/ethyl 
acetate 1:2. 
To prepare compounds D2-D5 an alternative synthetic route was followed. As 
described in Scheme 3 the reaction of 6-bromo carboxamide 5 with cesium 
carbonate in anhydrous DMF for 1 h under stirring at room temperature and 
then with p-fluorobenzyl chloride at 50°C for 24 h gave the N1 substituted 
derivative D2, purified by flash chromatography using toluene/ethyl acetate 14:1 
and 1% of acetic acid. In particular the separation of cis and trans isomers of D2 
was obtained together to the mixture of isomers. The two isomers were 
identified by the chemical shift of the proton in α position of amino group and 
the chemical shift of the protons of the methyl group of the carboxamide. In fact 
these values for the cis isomer (0.98 and 4.25 ppm) are in lower field than those 
of trans isomer (0.90 and 3.93 ppm).  
The 6-bromoderivative D2, as isomeric mixture, was subjected to a Cross 
Coupling reaction with the appropriate boronic acid (thienyl 2-boronic acid, p-
fluorophenyl-boronic acid and thiophen-2-boronic acid) in dioxane in the same 
conditions above reported for the preparation of compounds D1 to obtain the 
desired compound D3-D5 purified by flash chromatography. For compound D3 
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and D4 the separation of cis and trans isomers was obtained. The compound 
D5 was isolated as isomeric mixture. 
The synthetic route to obtain compounds E2-E5 is reported in Scheme 4. The 6-
bromoderivative 5 was treated with cesium carbonate in anhydrous DMF for 1 h 
under stirring at room temperature and then with 4-(2-chloroethyl)morpholine at 
70°C for 36 h to give the N1 substituted derivative E1. The Cross Coupling 
reaction of E1 with suitable boronic acid in dioxane under the Suzuki condition 
using Pd(Ph3)4 as catalyst and Na2CO3 2 M as base and carried out in 
microwave (CEM) at 150 °C for 15 min (power 200W, pressure 100 psi, stirring 
on) afforded the 6-substituted-1,8-naphthyridin-2(1H)-on derivatives E2-E5. 
These compounds were purified by flash chromatography and isolated as 
isomeric mixture. 
The binding affinities of newly compounds are currently underway at the 
Endocannabinoid Research Group of CNR in Pozzuoli and will be evaluated in 
competitive binding assays against [3H]CP-55,940 toward both human 
recombinant CB1 and CB2 receptors expressed in CHO cells. 
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SCHEME OF SYNTHESIS 
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SCHEME 1 
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1
2
C1-C5
N N
N
H
O
O
R
iv
C6-C8
 
 
 
 
Reagents and conditions: (i) diethyl malonate, piperidine, EtOH, reflux, 24 h; 
(ii) 4-methylcyclohexylamine, 120°C,  24 h; (iii) Cs2CO3 or NaH, RBr or RCl, 
DMF, 25-70°C, 12 h; (iv) NaOH 10%, reflux, 2-6 h. 
, 
C1: R=    ;                   C2: R= ;  
C3: R=; O
O
 ;      C4: R= O
O
;  
C5: R= O
O
;       C6: R= OH
O
 ;   
C7: R= OH
O
;             C8: R= OH
O
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SCHEME 2 
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Br
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Br
O
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O
O
i ii
iii
4
3
N N
N
H
O
O
F
O
N N
H
O
N
H
O
6
v
O
iv
O
5
D1
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Reagents and conditions:(i) Br2, AcOH, 24 h, 25°C; (ii) 
diethyl malonate, piperidine, EtOH, reflux, 24 h; (iii) 4-
methylcyclohexylamine, 120°C, 24 h; (iv) Ph3P, Pd(OAc)2, 
dioxane, Na2CO3, p-methoxybenzen boronic acid at 150°C in 
microwave (200 W, 100 Psi, 15 min., under stirring); (v) 
Cs2CO3, p-fluorobenzyl chloride, DMF, 50°C, 12 h. 
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SCHEME 3 
 
 
N N
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N N
Br
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F
N N
R
N
H
O
O
F
i
ii
D2
D3-D5
 
 
Reagents and conditions: (i) Cs2CO3, p-fluorobenzyl chloride, DMF, 50°C, 12 
h; (ii): Ph3P, Pd(OAc)2 , dioxane, Na2CO3, MeOH, RB(OH)2, at 150°C in 
microwave(200 W, 100 Psi, 15 min., under stirring). 
 
D3: R= 
O
    ; D4: R= 
S
   ;   D5: R= F  
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SCHEME 4 
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E1
E2-E5
i
 
 
  
  
 
 
 
                    
 
 
                     E2: R= O  ; E3: R= 
O
    ;  
 
                     E4: R= 
S
  ;    E5: R= F  
Reagents and conditions: (i) Cs2CO3, 4-(2-
chloroethyl)morpholine, DMF, 70°C, 36 h; (ii) Ph3P, 
Pd(OAc)2, dioxane, Na2CO3, MeOH, RB(OH)2 at 150°C in 
microwave (200 W, 100 Psi, 15 min., under stirring). 
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CHEMICAL EXPERIMENTAL SECTION 
 
Melting points were determined on a Kofler hot stage apparatus and are  
uncorrected.   
1H-NMR spectra were recorded with a Bruker AC-200 spectrometer in δ units 
from TMS as an internal standard. Analytical TLC was carried out on Merck 0.2 
mm precoated silica-gel glass plates (60 F-254) and location of spots was 
detected by illumination with a UV lamp. 
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EXPERIMENTAL PART 
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1,8-Naphthyrydin-2(1H)-on-3-carboxylic Acid Ethyl Ester    (1)  
N N
H
O
O
O
 
 
A mixture of 1.00 g (8.19 mmol) of 2-aminopirydin-3-carboxaldehyde, 1.83 mL 
(12.1 mmol) of diethyl malonate and 0.2 mL (2.05 mmol) of piperidine in 7.5 mL 
of  EtOH was heated to reflux for 24 h. After cooling the solid obtained was 
washed with EtOH and collected by filtration. 1.62 g of the pure derivative 1 was 
obtained by crystallization from ethyl acetate. 
                          
Yield: 91 % 
Mp: 182-185 °C 
 
1H-NMR:(DMSO) δ 1.29 (t ,3H, CH3); 4.37 (q, 2H, CH2); 7.29 (m, 1H, Ar); 8.26 
(dd, 1H, Ar); 8.50 (s,1H, Ar); 8.60 (dd,1H, Ar); 12.47 (br, 1H, NH). 
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N-(4-Methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-
carboxamide (2) 
 
N N
H
O
N
H
O
 
 
 
A mixture of 1.00 g (4.58 mmol) of compound 1 and 11.40 mL (9.16 mmol) of 4-
methylcyclohexylamine was heated in a sealed tube at 120°C for 24 h. After 
cooling, the reaction mixture was treated with diethyl ether to give 1.28 g of a 
solid residue which was collected by filtration and purified by crystallization from 
ethyl acetate. 
 
Yield: 98% 
 
 
1H-NMR: (DMSO) δ 0.89 and 0.92 (2d, 3H, CH3); 1.05-2.00 (m, 9H, cyclohexyl); 
3.85 and 4.11  (2m, 1H, CH); 7.36 (m,1H, Ar); 8.41 ( dd, 1H, Ar );  8.66 (dd, 1H, 
Ar); 8.85 (s, 1H, Ar); 9.60 and 10.01 (2d, 1H, NH); 11.85 (br ,1H , NH). 
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N-(4-Methylcyclohexyl)-1-butyl-1,8-naphthyridin-2(1H)-on-3-
carboxamide (C1) 
N N
N
H
O
O
 
An amount of 76 mg NaH (3.15 mmol ) was added to a solution of 0.30 g (1.05 
mmol) of carboxamide derivative 2 in 15 mL of anhydrous DMF and was stirred 
at room temperature. After 1h 0.36 mL (2.60 mmol) of 1-butyl bromide was 
added and the reaction mixture was stirred for 24h at room temperature. The 
reaction mixture was concentrated under reduced pressure and was treated 
with ice to give a solid residue which was collected by filtration and purified by 
flash chromatography using petroleum ether/ethyl acetate 2:1 as eluent to give 
0.220 g of C1.  
 
Yield: 61% 
 
 
1H-NMR: (CDCl3) δ 0.92-2.19 (m, 19H, 4-methylcyclohexyl+2CH2+CH3); 3.95 
and 4.26 (2m, 1H, CH); 4.61 (t, 2H, CH2 ); 7.27 (m, 1H, Ar); 8.06 (dd, 1H, Ar) ; 
8.73 (dd, 1H, Ar); 8.88 (s, 1H, Ar);  9.65 and 10.03 (2d, 1H, NH). 
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N-(4-Methylcyclohexyl)-1-pentyl-1,8-naphthyridin-2-(1H)-on-3-
carboxamide (C2) 
N N
N
H
O
O
 
An amount of 76 mg of NaH (3.15 mmol) was added to a solution of 
carboxamide derivative 2  0.30 g (1.05 mmol) in 15 mL of anhydrous DMF. After 
1 h 0.49 mL (4.10 mmol) of  1-pentyl chloride was added and the reaction 
mixture was stirred for 24h at room temperature. 
The mixture was concentrated under reduced pressure and treated with ice to 
give a solid residue which was collected by filtration and purified by 
crystallization with diisopropylether to obtain 0.32 g of C2. 
 
Yield: 85% 
 
 
1H-NMR: (CDCl3) δ 0.92-1.89 (m, 21H, 4-methycyclohexyl,+3CH2+CH3 ); 3.95 
and 4.26 (2m, 1H, CH);  4.57 (t, 2H, CH2); 7.27 (m, 1H, Ar); 8.07 (dd, 1H, Ar); 
8.70 (dd, 1H, Ar); 8.88 (s, 1H, Ar);  9.65 and 10.05 (2d, 1H, NH). 
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Ethyl 3-(N-(4-methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-
carboxamide) propanoate (C3) 
 
N N
O
N
H
OO
O
 
 
An amount of 1.96 g of Cs2CO3 (6.01 mmol) was added to a solution of 0.60 g 
(2.10  mmol) of carboxamide derivative 2 in 30 mL of anhydrous DMF. After 1 h 
1.05 mL (8.22 mmol) of ethyl-3-bromo propionate was added and the reaction 
mixture was left under stirring overnight at 60°C. 
After cooling the mixture was concentrated under reduced pressure and the 
residue was treated with ice to give a solid residue which was collected by 
filtration and purified by flash chromatography using toluene/ethyl acetate 1:2 as 
eluent to give 0.36 g of C3. 
  
Yield: 33% 
 
 
1H-NMR: (CDCl3) δ 0.92-2.11 (m, 15H, 4.methylcychloexyl+CH3); 2.81 (t, 2H, 
CH2); 3.95-4.26 (m, 3H, CH2+CH); 4.91 (t, 2H, CH2); 7.27 (m, 1H, Ar); 8.07 (dd, 
1H, Ar);8.70 (dd, 1H, Ar); 8.88 (s, 1H, Ar);  9.65 and 10.05 ( 2d, 1H, NH). 
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Ethyl 4-(N-(4-methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-
carboxamide) butanoate (C4) 
N N
N
H
O
O
O
O
 
 
An amount of 1.96 g of Cs2CO3 (6.01 mmol) was added to a solution of 0.60 g 
(2.10  mmol) of carboxamide derivative 2 in 30 mL of anhydrous DMF. After 1 h 
0.9mL (8.22 mmol) of ethyl 3-bromo butirate was added  and the reaction 
mixture was left under stirring overnight at 70°C. 
After cooling the mixture was concentrated under reduced pressure and the 
residue was treated with ice, to give a solid residue which was collected by flash 
chromatography using hexane/ethyl acetate 1:1 as eluent to obtain 0.21 g of 
C4. 
 
Yield: 28% 
 
 
1H-NMR: (CDCl3) δ 0.92-2.19 (m, 17H, 4-methylcyclohexyl+CH2+CH3); 2.46 (t, 
2H, CH2); 3.95-4.26 (m, 3H, CH2+CH); 4.69 (t, 2H, CH2); 7.27 (m, 1H, Ar); 8.07 
(dd, 1H, Ar); 8.70 (dd, 1H, Ar); 8.88 (s, 1H, Ar);  9.65 and 10.05 (2d, 1H, NH). 
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Methyl 5-(N-(4-methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-
carboxamide)  pentanoate (C5) 
N N
N
H
O
O
O O
 
An amount of 0.96 g of Cs2CO3  (3.00 mmol) and was added to a solution of 
0.30 g of 2 (1.05  mmol) in 15 mL of anhydrous DMF. After 1 h was added 0.30 
mL (2.1 mmol) of methyl 5-chloro valerate  and left under stirring overnight at 
50°C. 
After cooling the reaction mixture was concentrated under reduced pressure 
and the residue was treated with ice, to give a solid residue which was collected 
by filtration and purified by flash chromatography using hexane/ethyl acetate 1:2 
as eluent to obtain 0.110  g of C5. 
 
Yield: 29% 
 
 
 
1H-NMR: (CDCl3) δ 0.92-2.07 (m, 16H, 4.methylcyclohexyl+2CH2); 2.44 (t, 2H, 
CH2);  3.69 (s, 3H, CH3); 3.95 and 4.26 (2m, 1H, CH); 4.62 (t, 2H , CH2); 7.27 
(m, 1H, Ar); 8.07 (dd, 1H, Ar); 8.70 (dd, 1H, Ar); 8.88 (s, 1H, Ar); 9.65 and 10.05 
(2d, 1H, NH). 
 
  
 
 
 
 57 
Acid 3-(N-(4-methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-
carboxamide) propanoic (C6) 
N N
O
N
H
OHO
O
 
 
A solution of 80 mg (0.21 mmol) of C3 in 15 mL of NaOH 10% was heated at 
110°C. After 4 h the reaction mixture was treated with water and acidified with 
HCl conc. until acid pH. After the filtration it was obtained 71 mg of compound 
C6. 
 
Yield: 96% 
 
 
1H-NMR:(DMSO) δ 0.89-2.06 (m, 12H, 4-methylcyclohexyl); 2.89 (t, 2H, CH2); 
3.85 and 4.08 (2m, 1H, CH); 4.68 (t, 2H , CH2); 7.43 (m, 1H, Ar); 8.46 (dd, 1H, 
Ar); 8.76 (dd, 1H, Ar); 8.86 (s, 1H, Ar); 9.64 and 9.84 (2d, 1H, NH); 12.55 (s, 
1H, OH). 
 
 
 
 
 
 
 
 
 
 
 58 
Acid 4-(N-(4-methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-
carboxamide) butanoic (C7) 
N N
O
N
H
OH
O
O
 
 
 
A solution of 100 mg (0.27 mmol) of C4 in 15 mL of NaOH 10% was heated at 
110°C. After 6 h the reaction mixture was treated with water and acidified with 
HCl conc. until acid pH. After the filtration it was obtained 92 mg of compound 
C7. 
 
 
Yield: 92% 
 
 
 
1H-NMR(DMSO) δ 0.92-2.16 (m, 14H, 4-methylcyclohexyl+CH2); 2.49 (t, 2H, 
CH2); 3.85 and 4.10 (2m, 1H, CH); 4.56 (t, 2H, CH2); 7.44 (m, 1H, Ar); 8.49 (dd, 
1H, Ar); 8.78 (dd, 1H, Ar); 8.90 (s, 1H, Ar);  9.64 and 9.84 (2d, 1H, NH); 12.06 
(s, 1H, OH). 
 
 
 
 
 
 
 
 59 
Acid 5-(N-(4-methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-
carboxamide)  pentanoic (C8) 
 
N N
O
N
H
OHO
O
 
 
A solution of 80 mg (0.20 mmol) of C5 in 15 mL of NaOH 10% was heated at 
110°C. After 2 h the reaction mixture was treated with water and acidified with 
HCl conc. until acid pH. After the filtration it was obtained 73 mg of compound 
C8. 
 
 
 
Yield: 95% 
 
 
1H-NMR:(DMSO) δ 0.88-1.97 (m, 16H, 4-methylcyclohexyl+2CH2); 2.29 (t, 2H, 
CH2); 3.75 and 4.11 (2m, 1H, CH); 4.51 (t, 2H, CH2); 7.44 (m, 1H, Ar); 8.49 (dd, 
1H, Ar); 8.79 (dd, 1H, Ar); 8.89 (s, 1H, Ar); 9.58 and 9.94 (2d, 1H, NH); 12.05 
(s, 1H, OH). 
 
  
 
 
 
 
 
 60 
2-Amino-5-bromonicotinaldehyde (3) 
 
N
H
NH2
Br
O
 
 
Bromine (0.16 mL, 3.16 mmol) was added dropwise to solution of 2-
aminopyridin 3-carboxaldehyde (0.40 g, 3.30 mmol) in glacial acetic acid (15.6 
mL). The solution was stirred at room temperature for 24 h. The precipitate 
obtained was filtered and washed with diethyl ether.  The filter cake was poured 
into water and treated  with solid NaOH  until  pH 7-8. The mixture was 
extracted with dichloromethane. The organic layer was dried  with MgSO4 and 
evaporated to dryness under reduced pressure. The crude solid was purified by 
crystallization in acetonitrile to give 0.48 g of 3. 
 
 
Yield: 73% 
Mp: 145°-150°C 
 
H1 NMR: (DMSO) δ 5.27 (br, 2H, NH2); 8.27 (d,1H, Ar); 8.33 (d, 1H, Ar) ; 9.83 
(s, 1H, CHO). 
 
 
 
 
 
 
 
 
 
 
 
 61 
6-Bromo-1,8-naphthyridin-2-(1H)-on-3-carboxylic acid ethyl 
ester (4) 
 
N N
H
O
Br
O
O
 
 
 
A mixture of 1.6 g (7.92 mmol) of 3, 8.63 mL (12.1 mmol) of diethyl malonate 
and 2.8 mL (2.05 mmol) of piperidine in 28 mL of  EtOH was heated to reflux for 
24 h. After cooling the solid obtained was washed with EtOH and collected by 
filtration. It was obtained 2.32 g of crude product that was used without further 
purifications. 
 
Yield: 99% 
Mp: 200-203°C 
 
 
 
1H-NMR: (DMSO) δ 1.31 (t, 3H, CH3);  4.28 (q, 2H, CH2);  8.45 (s, 1H, Ar);  8.56 
(d,1H, Ar); 8.69 (d,1H, Ar); 12.64 (br, 1H, NH). 
 
 
 
 
 
 
 
 
 
 
 62 
N-(4-Methylcyclohexyl)-6-bromo-1,8-naphthyridin-2(1H)-on-3-
carboxamide (5) 
N N
H
N
H
Br
O
O
 
 
A mixture of 0.40 g (1.30 mmol) of compound 4 and 5.7 mL (3.9 mmol) of 4-
methylcyclohexylamine was heated in a sealed tube at 120°C for 24 h. After 
cooling, the reaction mixture was treated with diethyl ether to give a solid 
residue which was collected by filtration. It was obtained 0.31 g of crude product 
that was used without further purifications. 
 
 
Yield: 65% 
 
1H-NMR:(DMSO) δ 0.88-1.91 (m, 12H, 4-methylcyclohexyl); 3.78 and 4.12 (2m, 
1H, CH); 8.73-8.83 (m, 3H, Ar); 9.56 and 10.09 (2d, 1H, NH); 12.09 (br, 1H, 
NH). 
 
 
 
 
 
 
 
 
 
 
 
 
 63 
N-(4-Methylcyclohexyl)-6-(4-methoxyphenyl)-1,8-naphthyridin-
2(1H)-on-3-carboxamide   (6)   
 
N N
H
O
N
H
O
O
 
 
A mixture of 50 mg of Ph3 P(0.20 mmol) and 10 mg of Pd(OAc)2  (0.04 mmol) in 
dioxane, about 1mL, was left under stirring under N2 for 10 minutes. Then 150 
mg of 5 (0.41 mmol), 1 mL of MeOH, 0.82 mL of a solution of Na2CO3 10% and 
124 mg of 4-methoxybenzene boronic acid (0.82 mmol) was added. The 
mixture was heated in microwave (CEM) to 150°C for 10 minutes (power 200W, 
pressure 100 psi, stirring on). The residue was treated with CH2Cl2 and H2O; 
the organic layer was dried (MgSO4), filtered and evaporated under reduced 
pressure. The obtained residue was purified by flash chromatography using 
hexane/ethyl acetate 1:1 as eluent to give 80 mg of 6. 
 
Yield: 50%  
 
 
1H-NMR: (DMSO) δ 0.92-1.92 (m, 12H, 4-methylcyclohexyl); 3.83-4.12 (m, 4H, 
CH+CH3); 7.10 (d, 2H, phenyl), 7.75 (d, 2H, phenyl); 8.68 (s, 1H, Ar); 8.92 (s, 
1H, Ar); 8.98 (s, 1H, Ar); 9.65 and 10.05 (2d, 1H, NH); 12.93 (s, 1H, NH). 
 
 
 
 
 
 
 
 
 
 64 
N-(4-Methylcyclohexyl)-1-(4-fluorobenzyl)-6-(4-methoxyphenyl)-
1,8-naphthyridin-2(1H)-on-3-carboxamide (D1) 
N N
N
H
O
O
O
F  
 
An amount of 0.45 g of Cs2CO3 (1.28 mmol) was added to a solution of 0.18 g 
of 6 (0.46  mmol) in 20 mL of anhydrous DMF. After 1 h was added 0.10 mL 
(0.79 mmol) of p-fluorobenzyl chloride and left under stirring overnight at 50°C. 
After cooling the reaction mixture was concentrated under reduced pressure 
and the residue was treated with ice to give an orange solid. The solid was 
purified by flash chromatography using hexane/ethyl acetate 2:1 as eluent to 
give 97 mg of D1. 
 
Yield:42% 
 
 
1H-NMR(CDCl3): δ 0.92-2.05 (m, 12H, 4-methylcyclohexyl); 3.88 (s, 3H, CH3); 
3.95 and 4.26 (2m, 1H, CH);  5.82 (s, 2H, CH2); 7.06-7.58 (m, 8H, 
benzyl+phenyl); 8.18 (s, 1H, Ar); 8.91 (s, 1H, Ar); 8.98 (s, 1H, Ar) ; 9.65  and 
10.05 (2d, 1H, NH). 
 
 
 
 
 
 
 
 
 65 
 trans-N-(4-Methylcyclohexyl)-6-bromo-1-(p-fluorobenzyl)-1,8-
naphthyridin-2(1H)-on-3-carboxamide (trans-D2) and 
cis-N-(4-Methylcyclohexyl)-6-bromo-1-(p-fluorobenzyl)-1,8-
naphthyridin-2(1H)-on-3-carboxamide (cis-D2) 
N N
N
H
Br
O
O
F  
 
An amount of 0.75 g (2.30 mmol) of Cs2CO3 was added to a solution of 0.30 g 
of 5 (0.82 mmol) in 15 mL of anhydrous DMF. After 1 h was added 0.30 mL 
(2.10 mmol) of p-fluorobenzyl chloride and left under stirring overnight at 50 °C. 
After cooling, the reaction mixture was concentrated under reduced pressure 
and the residue was treated with ice to give a solid residue which was collected 
by filtration. The isomeric mixture was purified by flash chromatography using 
toluene/ethyl acetate 14:1 and 1% of acetic acid to give 61 mg of trans-D2  and 
30 mg of cis-D2.  
 
trans-D2 
Yield: 17% 
Mp:163-165°C 
 
 
1H-NMR: (CDCl3) δ 0.91 (d, 3H, CH3); 0.94-2.09 (m, 9H, cyclohexyl); 3.93 (m, 
1H, CH); 5.72 (s, 2H, CH2); 7.02 (m, 2H, benzyl); 7.45 (m, 1H, benzyl); 8.20 (s, 
1H, Ar); 8.72 (s, 1H, Ar); 8.82 (s, 1H, Ar); 9.50 (d, 1H, NH). 
 
 
 
 
 66 
cis-D2 
Yield: 8% 
Mp:158-160°C 
 
 
1H-NMR: (DMSO) δ  0.97 (d, 3H, CH3); 1.00-2.09 (m, 9H, cyclohexyl); 4.25 (m, 
1H, CH); 5.74 (s, 2H, CH2); 6.95 (m, 2H, benzyl); 7.47 (m, 2H, benzyl); 8.20 (s, 
1H, Ar); 8.73 (s,1H, Ar) 8.82 (s, 1H, Ar); 9.87 (d, 1H, NH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
trans-N-(4-Methylcyclohexyl)-1-(4-fluorobenzyl)-6-(furan-2-yl)- 
1,8-naphthyridin-2(1H)-on-3-carboxamide (trans-D3) and cis-N-
(4-Methylcyclohexyl)-1-(4-fluorobenzyl)-6-(furan-2-yl)- 1,8-
naphthyridin-2(1H)-on-3-carboxamide (cis-D3) 
N N O
N
H
OO
F  
A mixture of 34 mg of Ph3P (0.13 mmol) and 17 mg of Pd(OAc)2 (0.03 mmol) in 
dioxane, about 1mL, was left under stirring under N2 for 10 minutes. Then 125 
mg (0.26 mmol) of D2, 1 mL of MeOH, 0.52 mL of a solution of Na2CO3 10% 
and 60 mg of furan 2-boronic acid (0.52 mmol)  was added. The mixture was 
heated in microwave (CEM) to 150°C for 10 minutes (power 200W, pressure 
100 psi, stirring on). The residue was treated with CH2Cl2 and H2O; the organic 
layer was dried (MgSO4), filtered and evaporated under reduced pressure. The 
obtained residue was purified by flash chromatography using toluene/ethyl 
acetate 8:1 as eluent to give 39 mg of trans-D3 and 32 mg of cis-D3 
 
 
                         trans-D3 
Yield: 33% 
Mp: 175-178°C 
 
1H-NMR: (CDCl3) δ 0.94 (d, 3H, CH3); 0.98-2.06 (m, 9H, cyclohexyl); 3.95 (m, 
1H, CH); 5.80 (s, 2H, CH2); 6.55-7.56 (m, 7H, benzyl+furyl); 8.28 (s, 1H, Ar); 
8.93 (s, 1H, Ar); 8.98 (s, 1H, Ar); 9.60 (d,1H, NH). 
 
 
 
 
 
 68 
cis-D3 
Yield: 27% 
Mp: 168-170°C 
 
1H-NMR: (CDCl3) δ 0.99 (d, 3H, CH3); 1.02-2.37 (m, 9H, cyclohexyl); 4.27 (m, 
1H, CH); 5.80 (s, 2H, CH2); 6.55-7.57 (m, 7H, benzyl+furyl); 8.28 (s, 1H, Ar), 
8.93 (s, 1H, Ar); 9.02 (s, 1H, Ar); 9.99 (d, 1H, NH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 69 
trans-N-(4-Methylcyclohexyl)-1-(4-fluorobenzyl)-6-(thiophen-2-
yl)-1,8-naphthyridin-2(1H)-on-3-carboxamide  (trans-D4) and 
cis-N-(4-Methylcyclohexyl)-1-(4-fluorobenzyl)-6-(thiophen-2-yl)-
1,8-naphthyridin-2(1H)-on-3-carboxamide (cis-D4) 
N N
N
H
O
O
F
S
 
A mixture of 34 mg of Ph3P (0.12 mmol) and 17 mg of Pd(OAc)2  (0.02 mmol) in 
dioxane, about 1mL, was left under stirring under N2 for 10 minutes. Then 116 
mg of D2 (0.24 mmol), 1mL of MeOH, 0.52 mL of a solution of Na2CO3 10% and 
67 mg of tiophen 2-boronic acid (0.48 mmol) was added. The mixture was 
heated in microwave (CEM) to 150°C for 10 minutes (power 200W, pressure 
100 psi, stirring on). The residue was treated with CH2Cl2 and H2O; the organic 
layer was dried (MgSO4), filtered and evaporated under reduced pressure. The 
obtained residue was purified by flash chromatography using toluene/ethyl 
acetate 8:1 as eluent to give 27 mg of trans-D4 and 25 mg of cis-D4. 
 
 
trans-D4 
Yield: 24% 
Mp:169-171°C 
 
1H-NMR: (CDCl3) δ 0.92 (d, 3H, CH3); 0.94-2.07 (m, 9H, cyclohexyl); 3.95 (m,  
1H, CH); 5.79 (s, 2H, CH2); 7.03-7.52 (m, 7H, benzyl+thiophenyl); 8.21 (s, 1H, 
Ar); 8.93 (s,1H, Ar); 8.98 (s, 1H, Ar); 9.65 (d, 1H, NH). 
 
 
 
 
 70 
cis-D4  
Yield: 21% 
Mp: 167-170°C 
 
1H-NMR: (CDCl3)  δ 0.98 (d, 3H, CH3); 1.01-2.18 (m, 9H, cyclohexyl); 4.27 (m, 
1H, CH); 5.81 (s, 2H, CH2); 6.95-7.55 (m, 7H, benzyl+thiophenyl); 8.21 (s, 1H, 
Ar); 8.95 (s, 1H, Ar); 8.98 (s, 1H, Ar); 9.98 (d, 1H, NH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
N-(4-Methylcyclohexyl)-1-(4-fluorobenzyl)-6-(4-fluorophenyl)-
1,8-naphthyridin-2(1H)-on-3-carboxamide (D5) 
N N
N
H
O
O
F
F
 
 
A mixture of 34 mg of Ph3P (0.13 mmol) and 17 mg of Pd(OAc)2  (0.02 mmol) in 
dioxane, about 1 mL, was left under stirring under N2 for 10 minutes. Then 125 
mg of D2 (0.24 mmol), 1mL of MeOH, 0.52 mL of a solution of Na2CO3 10% and 
72 mg of p-fluorobenzen 2-boronic acid (0.48 mmol) was added. The mixture 
was heated in microwave (CEM) to 150°C for 10 minutes (power 200W, 
pressure 100 psi, stirring on). The residue was treated with CH2Cl2 and H2O; the 
organic layer was dried (MgSO4), filtered and evaporated under reduced 
pressure. The obtained residue was purified by flash chromatography using 
toluene/ethyl acetate 9:1 as eluent to give 112 mg of D5. 
 
Yield:96% 
 
1H-NMR(CDCl3): δ 0.92-2.06 (m, 12H, 4-methylcyclohexyl); 3.92 and 4.26 (2m, 
1H, CH); 5.80 (s, 2H, CH2);  7.04-7.63 (m, 8H, benzyl+phenyl); 8.21 (s, 1H, Ar); 
8.91 (s, 1H, Ar); 8.97 (s, 1H, Ar); 9.61 and 10.01 (2d, 1H, NH).  
 
 
 
 
 
 
 
 
 72 
N-(4-Methylcyclohexyl)-6-bromo-1-(2-morpholin-4-ylethyl)-1,8-
naphthyridin-2(1H)-on-3-carboxamide (E1) 
N N
N
H
Br
O
O
N
O  
An amount of 0.60 g (1.62 mmol) of Cs2CO3 was added to a solution of 0.21 g 
of 5 (0.58 mmol), in 10 mL of anhydrous DMF. After about an hour  was added 
0.32 g of 4-(2-chlorethyl)-morpholin hydrochloride (1.74 mmol),and stirred at 
70°C  for 36 h. After cooling the reaction mixture was concentrated under 
reduced pressure and the residue was treated with ice to give solid residue that 
was purified by crystallization in acetonitrile to obtain 0.25 g of E1. 
 
Yield:92% 
 
 
1H-NMR(CDCl3): δ 0.91-2.06 (m, 12H, 4-methylcyclohexyl); 2.59-2.75 (m, 6H, 
morpholine+CH2); 3.70 (m, 4H, morpholine); 3.95 and 4.10 (2m, 1H, CH); 4.73 
(t, 2H, CH2); 8.18 (d, 1H, Ar); 8.70 (d, 1H, Ar); 8.80 (s, 1H, Ar); 9.56 and 9.98 
(2d, 1H, NH). 
 
 
 
 
 
 
 
 73 
N-(4-Methylcyclohexyl)-6-(4-methoxyphenyl)-1-(2-morpholin-4-
ylethyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide (E2) 
N N
N
H
O
O
N
O
O
 
 
A mixture of 34 mg of Ph3 P(0.13 mmol) and 17 mg of Pd(OAc)2  (0.02 mmol) in 
dioxane, about 1 mL, was left under stirring under N2 for 10 minutes. Then 125 
mg of E1 (0.26 mmol), 1 mL of MeOH, 0.52 mL of a solution of Na2CO3 10% 
and 79 mg of 4-methoxybenzene boronic acid (0.52 mmol) was added. The 
mixture was heated in microwave (CEM) to 150°C for 10 minutes (power 200W, 
pressure 100 psi, stirring on). The residue was treated with CH2Cl2 and H2O; 
the organic layer was dried (MgSO4), filtered and evaporated under reduced 
pressure. The obtained residue was purified by flash chromatography using 
hexane/ethyl acetate 2:1 as eluent to give 63 mg of E2. 
 
Yield:48% 
 
1H-NMR: (CDCl3) δ 0.89-2.06 (m, 12H, 4-methylcyclohexyl); 2.63-2.80 (m, 6H, 
morpholine+CH2); 3.68 (m, 4H, morpholine); 3.89 (s, 3H, CH3); 3.95 and 4.26 
(2m, 1H, CH); 4.79 (t, 2H, CH2); 7.06 (m, 2H, phenyl); 7.59 (m, 2H, phenyl); 
8.17 (s, 1H, Ar); 8.89 (s, 1H, Ar); 8.93 (s, 1H, Ar);  9.65 and 10.05 ( 2d, 1H, NH). 
 
 
 
 
 
 74 
N-(4-Methylcyclohexyl)6-(furan-2-yl)-1-(2-morpholin-4-ylethyl)-
1,8-naphthyridin-2(1H)-on-3-carboxamide (E3) 
N N O
N
H
OO
N
O  
 
A mixture of 35 mg of Ph3P (0.13 mmol) and 18 mg of Pd(OAc)2 (0.03 mmol) in 
dioxane, about 1mL, was left under stirring under N2 for 10 minutes. Then 125 
mg of  E1 (0.26 mmol) , 1mL of MeOH,  0.52 mL of a solution of Na2CO3 10% 
and 60 mg of furan 2-boronic acid (0.52 mmol)  was added. The mixture was 
heated in microwave (CEM) to 150°C for 10 minutes (power 200W, pressure 
100 psi, stirring on). The residue was treated with CH2Cl2 and H2O; the organic 
layer was dried (MgSO4), filtered and evaporated under reduced pressure. The 
obtained residue was purified by flash chromatography using hexane/ethyl 
acetate 1:1 as eluent to give 95 mg of E3. 
 
Yield:79% 
 
1H-NMR: (CDCl3) δ 0.92-2.06 (m, 12H, 4-methylcyclohexyl); 2.63-2.79 (m, 6H, 
morpholine+CH2 ); 3.70 (m, 4H, morpholine); 3.95 and 4.26 (2m, 1H, CH); 4.82 
(t, 2H, CH2); 6.56 (m, 1H, furyl); 6.80 (d, 1H, furyl); 7.57 (d, 1H, furyl); 8.28 (s, 
1H, Ar); 8.91 (s, 1H, Ar); 8.98 (s, 1H, Ar); 9.64 and 10.05 (2d, 1H, NH).  
 
 
 
 
 
 
 75 
N-(4-Methylcyclohexyl)-1-(2-morpholin-4-ylethyl)-6-(thiophen-2-
yl)-1,8-naphthyridin-2(1H)-on-3-carboxamide (E4) 
 
N N
N
H
O
O
N
O
S
 
 
 
A mixture of 32 mg of Ph3P (0.12 mmol) and 16 mg of Pd(OAc)2  (0.02 mmol) in 
dioxane, about 1 mL, was left under stirring under N2 for 10 minutes. Then 116 
mg of E1 (0.24 mmol), 1mL of MeOH, 0.49 mL of a solution of Na2CO3 10% and 
62 mg of tiophen 2-boronic acid (0.48 mmol)  was added. The mixture was 
heated in microwave (CEM) to 150°C for 10 minutes (power 200W, pressure 
100 psi, stirring on). The residue was treated with CH2Cl2 and H2O; the organic 
layer was dried (MgSO4), filtered and evaporated under reduced pressure. The 
obtained residue was purified by flash chromatography using hexane/ethyl 
acetate 2:1 as eluent to give 91 mg of E4. 
 
Yield:79% 
 
1H-NMR: (CDCl3) δ 0.89-2.06 (m, 12H, 4-methylcyclohexyl); 2.64-2.76 (m, 6H, 
morpholine+CH2); 3.70 (m, 4H, morpholine); 3.95 and 4.26 (2m, 1H, CH); 4.80 
(t, 2H, CH2); 7.15 (m, 1H, thienyl); 7.42 (m, 2H, thienyl); 8.20 (s, 1H, Ar); 8.90 
(s, 1H, Ar); 8.96 (s, 1H, Ar); 9.65 and 10.03 (2d, 1H, NH). 
 
 
 
 
 76 
N-(4-Methylcyclohexyl)-6-(4-fluorophenyl)-1-(2-morpholin-4-
ylethyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide (E5) 
N N
N
H
O
O
F
N
O  
A mixture of 35 mg of Ph3P (0.13 mmol) and 18 mg of Pd(OAc)2  (0.03 mmol) in 
dioxane, about 1 mL, was left under stirring under N2 for 10 minutes. Then 125 
mg of E1 (0.26 mmol),  1 mL of MeOH, 0. 52 mL of a solution of Na2CO3 10% 
and 73 mg of p-fluorobenzen 2-boronic acid (0.46 mmol)  was added. The 
mixture was heated in microwave (CEM) to 150°C for 10 minutes (power 200W, 
pressure 100 psi, stirring on). The residue was treated with CH2Cl2 and H2O; the 
organic layer was dried (MgSO4), filtered and evaporated under reduced 
pressure. The obtained residue was purified by flash chromatography using 
hexane/ethyl acetate 1:1 as eluent to give 68 mg of E5. 
 
Yield:53% 
 
 
1H-NMR: (CDCl3) δ 0.89-2.05 (m, 12H, 4-methylcyclohexyl); 2.62-2.75 (m, 6H, 
morpholine+CH2); 3.70 (m, 4H, morpholine); 3.95 and 4.26 (2m, 1H, CH); 4.79 
(t, 2H, CH2 ); 7.18 (m, 2H, benzyl); 7.59 (m, 2H, benzyl); 8.17 (s, 1H, Ar); 8.87 
(s, 1H, Ar); 8.92 (s, 1H, Ar); 9.65 and 10.03 (2d, 1H, NH). 
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